Pacira BioSciences (PCRX) Accumulated Expenses (2010 - 2026)

Pacira BioSciences' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $85.0 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 6.1% year-over-year to $85.0 million in Q1 2026; TTM through Mar 2026 was $85.0 million, a 6.1% increase from a year earlier, with the FY2025 full-year figure at $95.6 million, up 19.32% from the prior year.
• Accumulated Expenses retreated to $85.0 million in Q1 2026 per PCRX's latest filing, from $95.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $95.6 million in Q4 2025 and bottomed at $56.2 million in Q2 2023.
• The 5-year median for Accumulated Expenses is $76.4 million (2024), against an average of $74.9 million.
• Across the five-year window, Accumulated Expenses jumped 74.5% in 2022 and dropped 29.7% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $89.8 million in 2022, then slipped by 28.45% to $64.2 million in 2023, then advanced by 24.72% to $80.1 million in 2024, then climbed by 19.32% to $95.6 million in 2025, then retreated by 11.13% to $85.0 million in 2026.
• Per Business Quant, the three latest PCRX Accumulated Expenses figures stand at $85.0 million (Q1 2026), $95.6 million (Q4 2025), and $79.6 million (Q3 2025).